


## SID 26681509

<b>Cat. No.:</b>	A4424
<b>CAS No.:</b>	958772-66-2
<b>Formula:</b>	C <sub>27</sub> H <sub>33</sub> N <sub>5</sub> O <sub>5</sub> S
<b>M.Wt:</b>	539.65
<b>Synonyms:</b>	
<b>Target:</b>	Proteases
<b>Pathway:</b>	Cathepsin
<b>Storage:</b>	Store at -20°C



## Solvent & Solubility

<26.98mg/ml in DMSO; <5.4mg/ml in ethanol

In Vitro

Preparing Stock Solutions	Mass		1mg	5mg	10mg
	Solvent	Concentration			
	1 mM		1.8531 mL	9.2653 mL	18.5305 mL
	5 mM		0.3706 mL	1.8531 mL	3.7061 mL
	10 mM		0.1853 mL	0.9265 mL	1.8531 mL

Please refer to the solubility information to select the appropriate solvent.

## Biological Activity

Shortsummary

Human cathepsin L inhibitor, potent and reversible

IC<sub>50</sub> & Target

56nM (cathepsin L)

In Vitro

### Cell Viability Assay

Cell Line:	human aortic endothelial cells
Preparation method:	The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.
Reacting conditions:	100 μM, 37°C for 24 h
Applications:	SID 26681509 (100 μM) was non-toxic to human aortic endothelial cells. SID

26681509 was active in an in vitro propagation assay against *P. falciparum* with an IC<sub>50</sub> of 15.4 ± 0.6 μM. SID 26681509 was toxic toward *L. major* promastigotes with an IC<sub>50</sub> of 12.5 ± 0.6 μM.

#### Animal experiment

Animal models: zebrafish

Dosage form: 100 μM

Applications: SID 26681509 (100 μM) demonstrated a lack of toxicity to zebrafish in a live organism assay.

Other notes: Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

In Vivo

## Product Citations

See more customer validations on [www.apexbt.com](http://www.apexbt.com).

## References

[1]. Shah P P, Myers M C, Beavers M P, et al. Kinetic characterization and molecular docking of a novel, potent, and selective slow-binding inhibitor of human cathepsin L[J]. *Molecular pharmacology*, 2008, 74(1): 34-41.

## Caution

**FOR RESEARCH PURPOSES ONLY.**

**NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.**

*Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.*

**APExBIO Technology**

[www.apexbt.com](http://www.apexbt.com)

7505 Fannin street, Suite 410, Houston, TX 77054.

2 | [www.apexbt.com](http://www.apexbt.com)

